ReviewJournal of clinical microbiology2019
Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa.
Review in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- The Need for a Revision of Fluoroquinolone Breakpoints for Interpretation of Antimicrobial Susceptibility Testing of Feline Bacterial Isolates.Journal of veterinary pharmacology and therapeutics · 2026Article
- Evolutionary trajectories determine feasibility of collateral sensitivity-based antibiotic treatment strategies in critical bacterial pathogens.Communications biology · 2025Article
- Antimicrobial resistance of uropathogens in diabetic patients.BMC infectious diseases · 2025Article
- The Rise, Fall, and Rethink of (Fluoro)quinolones: A Quick Rundown.Pathogens (Basel, Switzerland) · 2025Review
- Article
- Breakpoint drift: a hidden confounder in antimicrobial resistance surveillance?Frontiers in microbiology · 2025Article
- Fluoroquinolone resistance in ESKAPE pathogens: evolutionary pathways, one health transmission, and clinical surveillance.Frontiers in microbiology · 2025Review
- Oxidative stress induced by Etoposide anti-cancer chemotherapy drives the emergence of tumor-associated bacteria resistance to fluoroquinolones.Journal of advanced research · 2024Article
- Impact of Fluoroquinolone Susceptibility Suppression on Discharge Prescribing for Acute Uncomplicated Cystitis.Open forum infectious diseases · 2023Article
- Evaluating outcomes associated with revised fluoroquinolone breakpoints for Enterobacterales urinary tract infections: A retrospective cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Article
- RecA and Specialized Error-Prone DNA Polymerases Are Not Required for Mutagenesis and Antibiotic Resistance Induced by Fluoroquinolones inAntibiotics (Basel, Switzerland) · 2022Article
- The First Saudi Report of Novel and Common Mutations in theInfection and drug resistance · 2022Article
- Article
- The Practical Problem With Carbapenem Testing and Reporting Accurate Bacterial Susceptibilities.Frontiers in pharmacology · 2022Review
- Molecular Epidemiology ofInternational journal of microbiology · 2022Article
- Article
- Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation.Pharmaceutics · 2021Review
- QSAR Models for Active Substances againstMolecules (Basel, Switzerland) · 2021Article
- Impact of suppressing ciprofloxacin susceptibility results on antibiotic utilization and hospital-acquiredAntimicrobial stewardship & healthcare epidemiology : ASHE · 2021Article
- Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected withInfection and drug resistance · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluoroquinolones remain some of the more commonly prescribed antimicrobial agents in the United States, despite the wide array of reported side effects that are associated with their use. In 2019, the Clinical and Laboratory Standards Institute revised the fluoroquinolone antimicrobial susceptibility testing breakpoints for both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.